The global vaginal antifungals market enjoys a valuation of US$ 1.09 Billion in 2022, and it is further projected to expand at a CAGR of 4.5% over the forecasted years. According to a recent study by Future Market Insights, Polygenes are leading the market with a share of about 49.0% in the year 2022, within the global market.
Market Outlook
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 1.09 Billion |
| Market Value 2033 | US$ 1.76 Billion |
| CAGR 2023 to 2033 | 4.5% |
| Market Share of Top 5 Countries | 61.7% |
| Key Market Players | Pfizer Inc., Bausch Health Companies Inc., ANI Pharmaceuticals, Inc., Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals, PEPTONIC Medical AB, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, SCYNEXIS Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A.Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc. |
The signs of vaginal fungi infections include bloating near the vagina, burning when urinating, whitish-grey and clumpy vaginal discharge, and many others. Another name for vaginal yeast infection is candidiasis. Bacteria and a small number of yeast cells make up a healthy vagina, but when the ratio of bacteria to yeast changes, the yeast cells have the potential to multiply, which can further cause extreme itching, swelling, and irritation.
Antifungal medications prevent fungal infections from occurring by limiting the growth of fungus microorganisms on the host cell. As a result, the market is being favourably impacted by the availability of a variety of antifungal medications for the treatment of fungal infections as well as availability of over-the-counter medications.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global sales of the market are anticipated to rise at a CAGR of 4.5% between 2023 and 2033, owing to the rising prevalence of vaginal infectious disease.
The global vaginal antifungals market holds around 7.4% share of the overall global antifungals drug market with a value of around US$ 14.74 Billion, in 2022.
Vulvovaginal candidiasis (VVC), which mainly affects immunocompetent childbearing age women, frequently affects the lower female genital tract. Candida albicans is the pathogenic yeast that is most commonly linked to this fungus infection, excluding other non-albicans species.
Significant number of women, according to various scientists, have candida in their vaginas without exhibiting any signs. If the vaginal environment changes to favour Candida development, an infection may result. Hormones, medications, and immune system changes can all trigger infection. Additionally, among women of reproductive age, infectious organisms most frequently cause vulvovaginitis, or inflammation of the vulva and vagina. Candida vulvovaginitis is the root cause of around one-third of these instances.
The VVC emergence can be influenced by a variety of lifestyle factors. Although some studies suggest that excessive use of antibiotics and uncontrolled diabetes in women results in the vaginal fungal infections. Thus, the rising prevalence of diabetic patients in women is propelling the market.
Although, the market is being constrained by the reality that despite how many topical have been developed by the manufacturers, they are ineffective because they do not penetrate the skin well enough. However, the creation of novel products to enhance delivery, absorption, retention, and bioabsorbility in vulvovaginal tissue provides a significant market opportunity for manufacturers and drug developers.
Owing to the above-mentioned factors, the global market is expected to grow at a prominent pace, and reach a valuation of around US$ 1.76 Billion during the year 2033.
The market is anticipated to expand due to a rise in the vulvovaginal candidiasis in pregnant women and risk of fungal infection in diabetic patients.
Worldwide, pregnant women are affected by vulvovaginal candidiasis (VVC), a yeast infection of the vulva brought on by species of Candida. Due to a rise in the level of estrogen, which makes it easier for yeast to colonise the vagina pregnant women are more susceptible to developing VVC.
Similarly, antifungals are in high demand due to an increase in the danger of fungal infections in diabetic patients. Diabetes Mellitus has been linked to a number of health problems in women, including yeast infection. Diabetes, or unregulated blood glucose levels, can cause yeast overgrowth in warm and moist regions of the body, especially the vagina.
As a result, the increased risk of fungal infection in diabetes patients, as well as the desire for curative medication, are driving market expansion.
Principal Consultant
Due to medication side effects and a reduced detection rate as a result of asymptomatic fungal infections, the market is anticipated to slow down.
There is a need for the vaginal infections to be treated because the prevalence of fungi-related diseases is increasing globally. The absence of infection detection, however, is the main hindrance to market expansion. For instance, according to the Centers for Disease Control and Prevention, many fungi illnesses go undetected because of their vague symptoms. In addition, according to the article "Patient education: Bacterial vaginosis (Beyond the Basics)" in UpToDate 2023, around 50 to 75 percent of persons with BV have no symptoms. Hence, the lower detection rate is leading to a limited treatment rate for fungal infections, which is hampering the market.
Similar to this, the market is being gradually restrained by the negative effects of the medication used to treat vaginal fungal infections. For instance, vulvovaginal candidiasis is more common in pregnant women, making them essential for the treatment. Contrarily, animal studies by SCYNEXIS, Inc. suggest that administering the antifungal medication BREXAFEMME to pregnant women could damage the foetus. These serious drug side effects are preventing the industry from expanding. Additionally, diarrhoea, nausea, abdominal pain, and vomiting were the most frequent adverse reactions seen in clinical studies (incidence 2%). As a consequence, the market's development is constrained by the potent side effects of the drugs used to treat a fungus infection.
The USA dominates the global market with a total market share of around 27.0% in 2022, and the same rate of growth is anticipated to continue throughout the forecast period.
Rising prevalence of trichomoniasis in the country is supporting to the market growth for the vaginal antifungals.
Trichomoniasis can make it more probable for people to contract or spread HIV, and it increases the likelihood that women infected with the condition will deliver their babies prematurely and with low birth weights.
Therefore, with the increasing burden of fungal infection diseases, the demand for cure treatments is increasing, which is raising the market.
China has a market share of 12.8% in the global vaginal antifungals market in 2022 due to the upsurge in the high quality health care service in by the government.
As the cornerstone of integrated care, the Chinese government began to investigate the hierarchical diagnostic and treatment system. An institutional innovation in health care reform is the development of medical alliances, which enables hospitals and primary health care (PHC) facilities to collaborate closely to offer disease prevention, treatment, and rehabilitation services across the life course. By the end of 2019, China have created 12,000 medical alliances in order to mobilise high-quality healthcare services from public hospitals to PHC facilities.
Germany holds a market share of 7.6% in 2022 in the global vaginal antifungals market, owing to the government flutter to combat the infectious diseases.
Since 2016, Germany has been a steadfast supporter of Global Antibiotic Research and Development Partnership (GARDP) and has taken the lead in initiatives to combat antibiotic resistance. German government continues to be the largest contributor to GARDP with the new financing, increasing the entirety of its expenditures to EUR 116 million. Over the following five years (2023-2027), the German Federal Ministry of Education and Research pledged a further EUR 50 million in funds for the GARDP. The German financing will enable GARDP to develop novel antibiotic-resistant sickness therapies and ensure that everyone who requires them has access to them.
As a result, increased government funding for antibiotic resistance drugs is propelling the country's vaginal antifungals market.
India has a market share of 8.6% in the global vaginal antifungals market in 2022 due to the rising prevalence of vulvovaginal candidiasis.
Vulvovaginal candidiasis (VVC) is a clinical disease that is frequently seen in India. At least one episode of VVC occurs in at least three-fourths of all women's lifetimes. According to a study published in the Indian Journal of Obstetrics and Gynaecology Research, titled Vulvovaginal Candidiasis: Epidemiology, Treatment, and Prevention Strategies, the prevalence of VVC in India ranges from 10 to 35%.
So, topical treatments for short courses are useful in treating straightforward VVC. In 80%–90% of patients who complete therapy, azole treatment relieves symptoms and produces negative cultures according to CDC 2021. The success of oral and topical therapies for the VVC has led to an increase in the demand for antifungals.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Polygenes are expected to give high growth to the market and holding around 49.0% market share in 2022.
All common fungi that cause systemic infection, including species of Candida, Aspergillus, Mucor, and Cryptococcus, are responsive to amphotericin (belongs to the polyene class of antifungals). For infections caused by the aforementioned species, polyenes are very effective, which is leading to their high adoption. These medications are thought to be the most affordable, secure, and low-toxic antifungal agents available. Therefore, the demand is increasing because polyenes have fewer negative effects.
Topical administration is mostly preferred by the healthcare professional for the treatment purpose. It has a market share of 73.1% in the global market in 2022.
Due to their tailored therapy and limited adverse effects, topical fungal therapies are typically favoured. Due to their unique functional and structural characteristics, advanced topical transporters get beyond biopharmaceutical issues with traditional drug delivery systems, such as poor retention and low bioavailability. Additionally, continuous usage of antifungal medications has the potential to have negative side effects. In order to address this problem, patient cooperation is directed towards topical infection treatment. As a result, the market leader is the topical treatment category.
Bacterial vaginosis holds the market share of 44.9% during the year 2022.
A bacterial imbalance results in overgrowth of bacteria, which leads to bacterial vaginosis (BV), a common vaginal infection. The risk of bacterial vaginosis in pregnant women is increasing, which is also driving market expansion. Preterm birth, early miscarriage, postpartum endometritis, low birth weight, has been observed in women with bacterial vaginosis during pregnancy.
Gynaecology Clinics hold a market share of 41.4% during the year 2022. It is due to the high priority for the gynaecology clinics by the patients. The availability of specialised clinicians and high-tech treatment equipment attracts people to gynaecology clinics. Furthermore, the rising prevalence of vaginal infectious illnesses, combined with increased investment in infrastructure development, is increasing the usage of gynaecology clinics.
Leading companies in the global vaginal antifungals market are seeking for possibilities such as regional expansion to improve their market share. Furthermore, in order to boost their market presence, local rising companies are employing different methods such as mergers, cooperation, acquisition, agreement, and product launches and development in the vaginal antifungals market.
Similarly, recent developments related to companies manufacturing vaginal antifungals products have been tracked by the team at Future Market Insights. These are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2018 to 2022 |
| Historical Data Available for | 2023 to 2033 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and the Middle East & Africa |
| Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, The United kingdom, Germany, Italy, Russia, Spain, France, Benelux, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries and South Africa |
| Key Market Segments Covered | Product, Route of Administration, Indication, Distribution Channel, and Region |
| Key Companies Profiled | Pfizer Inc.; Bausch Health Companies Inc; ANI Pharmaceuticals, Inc.; Hikma Pharmaceuticals Plc; Lupin Limited; Mycovia Pharmaceuticals, Inc.; Glenmark Pharmaceuticals Limited; GSK plc.; Aurobindo Pharma Limited; Dr. Reddy's Laboratories; SCYNEXIS, Inc.; Basilea Pharmaceutica Ltd.; Astellas Pharma Inc.; Grupo Ferrer Internacional, S.A.; Pacgen Life Science Corporation; NovaDigm Therapeutics, Inc.; Cidara Therapeutics, Inc.; Amplyx Pharmaceuticals Inc. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The CAGR of the market is 4.5% through 2033.
The global market size to reach US$ 1.76 Billion by 2033.
With a market share of 27.0%, the United States governs the global market.
China possesses a 12.8% market share in the market.
The market has slowed notably owing to side effects from drugs and a lower identification rate as a consequence of asymptomatic fungal infections.
Due to a spike in vulvovaginal candidiasis in pregnant ladies and the potential of fungal infection in diabetics, the market is set to expand.
1. Executive Summary | Vaginal Antifungals Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value Added Insights
4.1. Product Adoption / Usage Analysis
4.2. Recent Product Launches
4.3. Disease Epidemiology
4.4. Patient Treatment Regime
4.5. Pipeline Assessment
4.6. Regulatory Scenario
4.7. PESTLE Analysis
4.8. Porter’s Analysis
4.9. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.1.3. Global Antifungal Drugs Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Key Player’s Historic Growth
5.2.2. New Product Launches / Approvals
5.2.3. Rising Prevalence of Vaginal Infectious Diseases
5.2.4. Demand for Minimally Invasive Treatment
5.2.5. High Incidence of Trichomoniasis
5.2.6. Growing Investment in Healthcare Expenditure
5.2.7. Government Support for Research and Developments
5.3. Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis – Impact Assessment
6.1. COVID-19 and Impact Analysis
6.1.1. By Product
6.1.2. By Route of Administration
6.1.3. By Indication
6.1.4. By Distribution Channel
6.1.5. By Region
6.2. 2022 Market Scenario
7. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis, 2018 to 2022
7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Product, 2018 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product, 2023 to 2033
8.3.1. Polyenes
8.3.2. Azoles
8.3.3. Allylamines
8.3.4. Echinocandins
8.3.5. Others
8.4. Market Attractiveness Analysis By Product
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2018 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
9.3.1. Oral
9.3.2. Topical
9.4. Market Attractiveness Analysis By Route of Administration
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Indication, 2018 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
10.3.1. Bacterial Vaginosis
10.3.2. Candidiasis
10.3.3. Trichomoniasis
10.3.4. Others
10.4. Market Attractiveness Analysis By Route of Administration
11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2018 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
11.3.1. Hospital Pharmacies
11.3.2. Supermarkets/hypermarkets
11.3.3. Online Pharmacies
11.3.4. Gynaecology Clinics
11.3.5. Others
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis By Region, 2018 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. South Asia
12.3.5. East Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (Middle East and Africa)
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. USA
13.3.1.2. Canada
13.3.2. By Product
13.3.3. By Route of Administration
13.3.4. By Indication
13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Product
13.4.3. By Route of Administration
13.4.4. By Indication
13.4.5. By Distribution Channel
13.5. Country Level Analysis & Forecast
13.5.1. USA Market Analysis
13.5.1.1. . Introduction
13.5.1.2. Market Analysis and Forecast by Market Taxonomy
13.5.1.2.1. By Product
13.5.1.2.2. By Route of Administration
13.5.1.2.3. By Indication
13.5.1.2.4. By Distribution Channel
13.5.2. Canada Market Analysis
13.5.2.1. Introduction
13.5.2.2. Market Analysis and Forecast by Market Taxonomy
13.5.2.2.1. By Product
13.5.2.2.2. By Route of Administration
13.5.2.2.3. By Indication
13.5.2.2.4. By Distribution Channel
13.6. Market Trends
13.7. Key Market Participants - Intensity Mapping
13.8. Drivers and Restraints - Impact Analysis
14. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Product
14.3.3. By Route of Administration
14.3.4. By Indication
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product
14.4.3. By Route of Administration
14.4.4. By Distribution Channel
14.5. Country Level Analysis & Forecast
14.5.1. Brazil Market Analysis
14.5.1.1. . Introduction
14.5.1.2. Market Analysis and Forecast by Market Taxonomy
14.5.1.2.1. By Product
14.5.1.2.2. By Route of Administration
14.5.1.2.3. By Indication
14.5.1.2.4. By Distribution Channel
14.5.2. Mexico Market Analysis
14.5.2.1. Introduction
14.5.2.2. Market Analysis and Forecast by Market Taxonomy
14.5.2.2.1. By Product
14.5.2.2.2. By Route of Administration
14.5.2.2.3. By Indication
14.5.2.2.4. By Distribution Channel
14.5.3. Argentina Market Analysis
14.5.3.1. Introduction
14.5.3.2. Market Analysis and Forecast by Market Taxonomy
14.5.3.2.1. By Product
14.5.3.2.2. By Route of Administration
14.5.3.2.3. By Indication
14.5.3.2.4. By Distribution Channel
14.6. Market Trends
14.7. Key Market Participants - Intensity Mapping
14.8. Drivers and Restraints - Impact Analysis
15. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. France
15.3.1.3. Italy
15.3.1.4. United kingdom
15.3.1.5. Spain
15.3.1.6. Russia
15.3.1.7. BENELUX
15.3.1.8. Nordic Countries
15.3.1.9. Rest of Europe
15.3.2. By Product
15.3.3. By Route of Administration
15.3.4. By Indication
15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Route of Administration
15.4.4. By Indication
15.4.5. By Distribution Channel
15.5. Country Level Analysis & Forecast
15.5.1. Germany Market Analysis
15.5.1.1. . Introduction
15.5.1.2. Market Analysis and Forecast by Market Taxonomy
15.5.1.2.1. By Product
15.5.1.2.2. By Route of Administration
15.5.1.2.3. By Indication
15.5.1.2.4. By Distribution Channel
15.5.2. France Market Analysis
15.5.2.1. Introduction
15.5.2.2. Market Analysis and Forecast by Market Taxonomy
15.5.2.2.1. By Product
15.5.2.2.2. By Route of Administration
15.5.2.2.3. By Indication
15.5.2.2.4. By Distribution Channel
15.5.3. Italy Market Analysis
15.5.3.1. Introduction
15.5.3.2. Market Analysis and Forecast by Market Taxonomy
15.5.3.2.1. By Product
15.5.3.2.2. By Route of Administration
15.5.3.2.3. By Indication
15.5.3.2.4. By Distribution Channel
15.5.4. United kingdom Market Analysis
15.5.4.1. . Introduction
15.5.4.2. Market Analysis and Forecast by Market Taxonomy
15.5.4.2.1. By Product
15.5.4.2.2. By Route of Administration
15.5.4.2.3. By Indication
15.5.4.2.4. By Distribution Channel
15.5.5. Spain Market Analysis
15.5.5.1. . Introduction
15.5.5.2. Market Analysis and Forecast by Market Taxonomy
15.5.5.2.1. By Product
15.5.5.2.2. By Route of Administration
15.5.5.2.3. By Indication
15.5.5.2.4. By Distribution Channel
15.5.6. Russia Market Analysis
15.5.6.1. . Introduction
15.5.6.2. Market Analysis and Forecast by Market Taxonomy
15.5.6.2.1. By Product
15.5.6.2.2. By Route of Administration
15.5.6.2.3. By Indication
15.5.6.2.4. By Distribution Channel
15.5.7. Nordic Countries Market Analysis
15.5.7.1. . Introduction
15.5.7.2. Market Analysis and Forecast by Market Taxonomy
15.5.7.2.1. By Product
15.5.7.2.2. By Route of Administration
15.5.7.2.3. By Indication
15.5.7.2.4. By Distribution Channel
15.5.8. BENELUX Market Analysis
15.5.8.1. . Introduction
15.5.8.2. Market Analysis and Forecast by Market Taxonomy
15.5.8.2.1. By Product
15.5.8.2.2. By Route of Administration
15.5.8.2.3. By Indication
15.5.8.2.4. By Distribution Channel
15.6. Market Trends
15.7. Key Market Participants - Intensity Mapping
15.8. Drivers and Restraints - Impact Analysis
16. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Thailand
16.3.1.3. Indonesia
16.3.1.4. Malaysia
16.3.1.5. Rest of South Asia
16.3.2. By Product
16.3.3. By Route of Administration
16.3.4. By Indication
16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Route of Administration
16.4.4. By Indication
16.4.5. By Distribution Channel
16.5. Country Level Analysis & Forecast
16.5.1. India Market Analysis
16.5.1.1. . Introduction
16.5.1.2. Market Analysis and Forecast by Market Taxonomy
16.5.1.2.1. By Product
16.5.1.2.2. By Route of Administration
16.5.1.2.3. By Indication
16.5.1.2.4. By Distribution Channel
16.5.2. Thailand Market Analysis
16.5.2.1. . Introduction
16.5.2.2. Market Analysis and Forecast by Market Taxonomy
16.5.2.2.1. By Product
16.5.2.2.2. By Route of Administration
16.5.2.2.3. By Indication
16.5.2.2.4. By Distribution Channel
16.5.3. Indonesia Market Analysis
16.5.3.1. Introduction
16.5.3.2. Market Analysis and Forecast by Market Taxonomy
16.5.3.2.1. By Product
16.5.3.2.2. By Route of Administration
16.5.3.2.3. By Indication
16.5.3.2.4. By Distribution Channel
16.5.4. Malaysia Market Analysis
16.5.4.1. Introduction
16.5.4.2. Market Analysis and Forecast by Market Taxonomy
16.5.4.2.1. By Product
16.5.4.2.2. By Route of Administration
16.5.4.2.3. By Indication
16.5.4.2.4. By Distribution Channel
16.6. Market Trends
16.7. Key Market Participants - Intensity Mapping
16.8. Drivers and Restraints - Impact Analysis
17. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Product
17.3.3. By Route of Administration
17.3.4. By Indication
17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Route of Administration
17.4.4. By Indication
17.4.5. By Distribution Channel
17.5. Country Level Analysis & Forecast
17.5.1. China Market Analysis
17.5.1.1. . Introduction
17.5.1.2. Market Analysis and Forecast by Market Taxonomy
17.5.1.2.1. By Product
17.5.1.2.2. By Route of Administration
17.5.1.2.3. By Indication
17.5.1.2.4. By Distribution Channel
17.5.2. Japan Market Analysis
17.5.2.1. Introduction
17.5.2.2. Market Analysis and Forecast by Market Taxonomy
17.5.2.2.1. By Product
17.5.2.2.2. By Route of Administration
17.5.2.2.3. By Indication
17.5.2.2.4. By Distribution Channel
17.5.3. South Korea Market Analysis
17.5.3.1. Introduction
17.5.3.2. Market Analysis and Forecast by Market Taxonomy
17.5.3.2.1. By Product
17.5.3.2.2. By Route of Administration
17.5.3.2.3. By Indication
17.5.3.2.4. By Distribution Channel
17.6. Market Trends
17.7. Key Market Participants - Intensity Mapping
17.8. Drivers and Restraints - Impact Analysis
18. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Product
18.3.3. By Route of Administration
18.3.4. By Indication
18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product
18.4.3. By Route of Administration
18.4.4. By Indication
18.4.5. By Distribution Channel
18.5. Country Level Analysis & Forecast
18.5.1. Australia Market Analysis
18.5.1.1. . Introduction
18.5.1.2. Market Analysis and Forecast by Market Taxonomy
18.5.1.2.1. By Product
18.5.1.2.2. By Route of Administration
18.5.1.2.3. By Indication
18.5.1.2.4. By Distribution Channel
18.5.2. New Zealand Market Analysis
18.5.2.1. Introduction
18.5.2.2. Market Analysis and Forecast by Market Taxonomy
18.5.2.2.1. By Product
18.5.2.2.2. By Route of Administration
18.5.2.2.3. By Indication
18.5.2.2.4. By Distribution Channel
18.6. Market Trends
18.7. Key Market Participants - Intensity Mapping
18.8. Drivers and Restraints - Impact Analysis
19. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Türkiye
19.3.1.3. Northern Africa
19.3.1.4. South Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Product
19.3.3. By Route of Administration
19.3.4. By Indication
19.3.5. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Product
19.4.3. By Route of Administration
19.4.4. By Indication
19.4.5. By Distribution Channel
19.5. Country Level Analysis & Forecast
19.5.1. GCC Countries Market Analysis
19.5.1.1. . Introduction
19.5.1.2. Market Analysis and Forecast by Market Taxonomy
19.5.1.2.1. By Product
19.5.1.2.2. By Route of Administration
19.5.1.2.3. By Indication
19.5.1.2.4. By Distribution Channel
19.5.2. Türkiye Market Analysis
19.5.2.1. Introduction
19.5.2.2. Market Analysis and Forecast by Market Taxonomy
19.5.2.2.1. By Product
19.5.2.2.2. By Route of Administration
19.5.2.2.3. By Indication
19.5.2.2.4. By Distribution Channel
19.5.3. Northern Africa Market Analysis
19.5.3.1. Introduction
19.5.3.2. Market Analysis and Forecast by Market Taxonomy
19.5.3.2.1. By Product
19.5.3.2.2. By Route of Administration
19.5.3.2.3. By Indication
19.5.3.2.4. By Distribution Channel
19.5.4. South Africa Market Analysis
19.5.4.1. Introduction
19.5.4.2. Market Analysis and Forecast by Market Taxonomy
19.5.4.2.1. By Product
19.5.4.2.2. By Route of Administration
19.5.4.2.3. By Indication
19.5.4.2.4. By Distribution Channel
19.6. Market Trends
19.7. Key Market Participants - Intensity Mapping
19.8. Drivers and Restraints - Impact Analysis
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Branding and Promotional Strategies, By Key Players
21.3. Key Development Analysis
21.4. Competition Deep Dive
21.4.1. Pfizer Inc.
21.4.1.1. Overview
21.4.1.2. Product Portfolio
21.4.1.3. Key Financials
21.4.1.4. SWOT Analysis
21.4.1.5. Key Developments
21.4.1.6. Sales Footprint
21.4.1.7. Strategy Overview
21.4.1.7.1. Marketing Strategy
21.4.1.7.2. Product Strategy
21.4.1.7.3. Channel Strategy
21.4.2. Bausch Health Companies Inc
21.4.2.1. Overview
21.4.2.2. Product Portfolio
21.4.2.3. Key Financials
21.4.2.4. SWOT Analysis
21.4.2.5. Key Developments
21.4.2.6. Sales Footprint
21.4.2.7. Strategy Overview
21.4.2.7.1. Marketing Strategy
21.4.2.7.2. Product Strategy
21.4.2.7.3. Channel Strategy
21.4.3. ANI Pharmaceuticals, Inc.
21.4.3.1. Overview
21.4.3.2. Product Portfolio
21.4.3.3. Key Financials
21.4.3.4. SWOT Analysis
21.4.3.5. Key Developments
21.4.3.6. Sales Footprint
21.4.3.7. Strategy Overview
21.4.3.7.1. Marketing Strategy
21.4.3.7.2. Product Strategy
21.4.3.7.3. Channel Strategy
21.4.4. Hikma Pharmaceuticals Plc
21.4.4.1. Overview
21.4.4.2. Product Portfolio
21.4.4.3. Key Financials
21.4.4.4. SWOT Analysis
21.4.4.5. Key Developments
21.4.4.6. Sales Footprint
21.4.4.7. Strategy Overview
21.4.4.7.1. Marketing Strategy
21.4.4.7.2. Product Strategy
21.4.4.7.3. Channel Strategy
21.4.5. Lupin Limited
21.4.5.1. Overview
21.4.5.2. Product Portfolio
21.4.5.3. Key Financials
21.4.5.4. SWOT Analysis
21.4.5.5. Key Developments
21.4.5.6. Sales Footprint
21.4.5.7. Strategy Overview
21.4.5.7.1. Marketing Strategy
21.4.5.7.2. Product Strategy
21.4.5.7.3. Channel Strategy
21.4.6. Mycovia Pharmaceuticals, Inc.
21.4.6.1. Overview
21.4.6.2. Product Portfolio
21.4.6.3. Key Financials
21.4.6.4. SWOT Analysis
21.4.6.5. Key Developments
21.4.6.6. Sales Footprint
21.4.6.7. Strategy Overview
21.4.6.7.1. Marketing Strategy
21.4.6.7.2. Product Strategy
21.4.6.7.3. Channel Strategy
21.4.7. Glenmark Pharmaceuticals Limited
21.4.7.1. Overview
21.4.7.2. Product Portfolio
21.4.7.3. Key Financials
21.4.7.4. SWOT Analysis
21.4.7.5. Key Developments
21.4.7.6. Sales Footprint
21.4.7.7. Strategy Overview
21.4.7.7.1. Marketing Strategy
21.4.7.7.2. Product Strategy
21.4.7.7.3. Channel Strategy
21.4.8. GSK plc.
21.4.8.1. Overview
21.4.8.2. Product Portfolio
21.4.8.3. Key Financials
21.4.8.4. SWOT Analysis
21.4.8.5. Key Developments
21.4.8.6. Sales Footprint
21.4.8.7. Strategy Overview
21.4.8.7.1. Marketing Strategy
21.4.8.7.2. Product Strategy
21.4.8.7.3. Channel Strategy
21.4.9. Aurobindo Pharma Limited
21.4.9.1. Overview
21.4.9.2. Product Portfolio
21.4.9.3. Key Financials
21.4.9.4. SWOT Analysis
21.4.9.5. Key Developments
21.4.9.6. Sales Footprint
21.4.9.7. Strategy Overview
21.4.9.7.1. Marketing Strategy
21.4.9.7.2. Product Strategy
21.4.9.7.3. Channel Strategy
21.4.10. Dr. Reddy's Laboratories
21.4.10.1. Overview
21.4.10.2. Product Portfolio
21.4.10.3. Key Financials
21.4.10.4. SWOT Analysis
21.4.10.5. Key Developments
21.4.10.6. Sales Footprint
21.4.10.7. Strategy Overview
21.4.10.7.1. Marketing Strategy
21.4.10.7.2. Product Strategy
21.4.10.7.3. Channel Strategy
21.4.11. SCYNEXIS, Inc.
21.4.11.1. Overview
21.4.11.2. Product Portfolio
21.4.11.3. Key Financials
21.4.11.4. SWOT Analysis
21.4.11.5. Key Developments
21.4.11.6. Sales Footprint
21.4.11.7. Strategy Overview
21.4.11.7.1. Marketing Strategy
21.4.11.7.2. Product Strategy
21.4.11.7.3. Channel Strategy
21.4.12. Basilea Pharmaceutica Ltd.
21.4.12.1. Overview
21.4.12.2. Product Portfolio
21.4.12.3. Key Financials
21.4.12.4. SWOT Analysis
21.4.12.5. Key Developments
21.4.12.6. Sales Footprint
21.4.12.7. Strategy Overview
21.4.12.7.1. Marketing Strategy
21.4.12.7.2. Product Strategy
21.4.12.7.3. Channel Strategy
21.4.13. Astellas Pharma Inc.
21.4.13.1. Overview
21.4.13.2. Product Portfolio
21.4.13.3. Key Financials
21.4.13.4. SWOT Analysis
21.4.13.5. Key Developments
21.4.13.6. Sales Footprint
21.4.13.7. Strategy Overview
21.4.13.7.1. Marketing Strategy
21.4.13.7.2. Product Strategy
21.4.13.7.3. Channel Strategy
21.4.14. Grupo Ferrer Internacional, S.A.
21.4.14.1. Overview
21.4.14.2. Product Portfolio
21.4.14.3. Key Financials
21.4.14.4. SWOT Analysis
21.4.14.5. Key Developments
21.4.14.6. Sales Footprint
21.4.14.7. Strategy Overview
21.4.14.7.1. Marketing Strategy
21.4.14.7.2. Product Strategy
21.4.14.7.3. Channel Strategy
21.4.15. Pacgen Life Science Corporation
21.4.15.1. Overview
21.4.15.2. Product Portfolio
21.4.15.3. Key Financials
21.4.15.4. SWOT Analysis
21.4.15.5. Key Developments
21.4.15.6. Sales Footprint
21.4.15.7. Strategy Overview
21.4.15.7.1. Marketing Strategy
21.4.15.7.2. Product Strategy
21.4.15.7.3. Channel Strategy
21.4.16. NovaDigm Therapeutics, Inc.
21.4.16.1. Overview
21.4.16.2. Product Portfolio
21.4.16.3. Key Financials
21.4.16.4. SWOT Analysis
21.4.16.5. Key Developments
21.4.16.6. Sales Footprint
21.4.16.7. Strategy Overview
21.4.16.7.1. Marketing Strategy
21.4.16.7.2. Product Strategy
21.4.16.7.3. Channel Strategy
21.4.17. Cidara Therapeutics, Inc.
21.4.17.1. Overview
21.4.17.2. Product Portfolio
21.4.17.3. Key Financials
21.4.17.4. SWOT Analysis
21.4.17.5. Key Developments
21.4.17.6. Sales Footprint
21.4.17.7. Strategy Overview
21.4.17.7.1. Marketing Strategy
21.4.17.7.2. Product Strategy
21.4.17.7.3. Channel Strategy
21.4.18. Amplyx Pharmaceuticals Inc.
21.4.18.1. Overview
21.4.18.2. Product Portfolio
21.4.18.3. Key Financials
21.4.18.4. SWOT Analysis
21.4.18.5. Key Developments
21.4.18.6. Sales Footprint
21.4.18.7. Strategy Overview
21.4.18.7.1. Marketing Strategy
21.4.18.7.2. Product Strategy
21.4.18.7.3. Channel Strategy
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Vaginal Antifungals Market
